Fate of the antimetastatic ruthenium complex ImH[trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice
| Autor: | Cocchietto M, Salerno G, Alessio E, Mestroni G, Gianni Sava |
|---|---|
| Přispěvatelé: | Cocchietto, M., Salerno, G., Alessio, Enzo, Mestroni, G., Sava, Gianni |
| Jazyk: | angličtina |
| Rok vydání: | 2000 |
| Předmět: |
NAMI-A
Animal studies Pharmacokinetics Antineoplastic Agents Body Fluid Compartments Models Biological Mice Animal studie Area Under Curve Injections Intravenous Mice Inbred CBA Organometallic Compounds Animals Ruthenium Compounds Dimethyl Sulfoxide Kidney Diseases Tissue Distribution Neoplasm Metastasis |
| Zdroj: | Scopus-Elsevier Europe PubMed Central |
| Popis: | The content of ruthenium in blood and different organs of healthy CBA mice was determined by AAS after single i.v. treatment of 200 mg kg-1 of NAMI-A, a new antimetastatic ruthenium compound. Ruthenium concentration in blood falls 5 min after i.v. treatment. In the kidney, ruthenium concentration is markedly higher than in any other analysed tissue. No ruthenium was detected in brains. Pharmacokinetic parameters for a mono- or a bi-compartment model are identifiable: t1/2 is 10.45 h vs 12.02 (t1/2 alpha 0.023 h + t1/2 beta 12 h) with Cltot of 1.60 ml*h-1 vs 1.59); Vd is 24.15 vs 27.48 ml and (model dependent) AUC is 689 vs 694 mg*L-1*h. AUC(0--infinity) calculated by noncompartmental method (linear trapezoidal rule) is 719.77 mg*L-1*h. NAMI-A is rapidly cleared from the blood compartment immediately after i.v. administration. Apparently, there is no differential accumulation of ruthenium in the lungs which might account for a selective antimetastatic effect caused by a cytotoxic concentration in this site, nor in any other specific organ examined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|